Table 4.
Crude and overlap propensity score weighted odds ratios of dates of statin prescriptions for overall mortality in gastric cancer participants.
| Characteristics | Deceased | Survived | Odds Ratios for Mortality (95% Confidence Interval) | |||
|---|---|---|---|---|---|---|
| % | % | Crude | p-Value | Overlap Weighted Model † | p-Value | |
| Any statin | ||||||
| <180 days | 91.1 | 86.5 | 1 | 1 | ||
| 180–545 days | 4.7 | 6.0 | 0.74 (0.60–0.93) | 0.008 * | 1.15 (0.94–1.40) | 0.164 |
| >545 days | 4.2 | 7.4 | 0.53 (0.42–0.67) | <0.001 * | 0.85 (0.69–1.04) | 0.106 |
| Hydrophilic statins | ||||||
| <180 days | 98.5 | 97.5 | 1 | 1 | ||
| 180–545 days | 0.6 | 1.3 | 0.47 (0.27–0.83) | 0.009 * | 0.47 (0.29–0.77) | 0.003 * |
| >545 days | 0.9 | 1.2 | 0.75 (0.46–1.22) | 0.243 | 1.17 (0.75–1.81) | 0.495 |
| Lipophilic statins | ||||||
| <180 days | 92.5 | 88.7 | 1 | 1 | ||
| 180–545 days | 4.4 | 5.6 | 0.76 (0.61–0.95) | 0.016 * | 1.21 (0.99–1.49) | 0.064 |
| >545 days | 3.0 | 5.7 | 0.51 (0.39–0.66) | <0.001 * | 0.82 (0.65–1.03) | 0.086 |
The total numbers of deceased participants and surviving participants were 2309 and 6489, respectively. * Significance at p < 0.05. † Adjusted for age, sex, income, region of residence, systolic blood pressure, diastolic blood pressure, fasting blood glucose, total cholesterol, obesity, smoking, alcohol consumption, dyslipidemia history, and Charlson Comorbidity Index (CCI) scores.